Homeopathy 2012; 101(04): 217-223
DOI: 10.1016/j.homp.2012.08.005
Original Paper
Copyright © The Faculty of Homeopathy 2012

Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial

A.K. Hati
1  Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
B. Paitala
2  Department of Zoology and Biotechnology, Utkal University, Bhubaneswar 751 004, India
,
K.N. Naik
1  Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
A.K. Mishra
1  Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
,
G.B.N. Chainyb
2  Department of Zoology and Biotechnology, Utkal University, Bhubaneswar 751 004, India
,
L.K. Nanda
1  Dr. Abhin Chandra Homoeopathic Medical College & Hospital, Unit-III, Bhubaneswar, 751 001 Odisha, India
› Author Affiliations

Subject Editor:
Further Information

Publication History

Received16 February 2011
revised18 July 2012

accepted06 August 2012

Publication Date:
02 January 2018 (online)

Background: Benign Prostatic Hypertrophy (BPH) is common in older men. This study compared homeopathic treatment strategies using constitutional medicines (CM) or organopathic medicines (OM) alone or in combination (BCOM) in patients suffering from BPH.

Methods: 220 men aged 30–90 years were recruited in Odisha, India. Patients presenting symptoms of prostatism, with or without evidence of bladder outflow obstruction were included in the study. Patients with serum prostate specific antigen (PSA)> 4 nmol/mL, malignancy, complete urine retention, stone formation and gross bilateral hydronephrosis were excluded. Patients were sequentially allocated to OM, CM or BCOM. The main outcome measure was the International Prostate Symptom Score (IPSS).

Results: 73, 70 and 77 patients respectively were sequentially allocated to OM, CM or BCOM. 180 patients (60 per group) completed treatment and were included in the final analysis. Overall 85% of patients showed improvement of subjective symptoms such as frequency, urgency, hesitancy, intermittent flow, unsatisfactory urination, feeble stream, diminution of residual urine volume but there was no reduction in prostate size. Treatment response was highest with BCOM (38.24%) compared to OM (31.62%) and CM (30.15%). Effect sizes were highest for the decrease in IPSS, residual urine volume and urinary flow rate.

a Present address: Biochemical Adaptation Lab., Department of Zoology, Banaras Hindu University, Varanasi 221005, UP, India. Tel.: +91 542 6702523; fax: +91 542 2368174.


b Present address: Imgenex India Pvt. Ltd., E-5, Infocity, Bhubaneswar 751024, India. Tel.: +91 674 3296544; fax: +91 674 2741046.